NASDAQ:SRZN Surrozen Q3 2025 Earnings Results & Report $31.88 -0.76 (-2.33%) Closing price 11/11/2026 04:00 PM EasternExtended Trading$31.96 +0.08 (+0.24%) As of 08:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Surrozen missed analyst earnings expectations in its Q3 2025 results, released November 7, 2025. The company reported EPS of -$3.61 versus the -$1.17 consensus estimate, while revenue was $983 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 7, 2025TimeBefore Market OpensConference Call4:00 PM ET Surrozen EPS ResultsActual EPS-$3.61Consensus EPS -$1.17Beat/MissMissed by -$2.44One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersSurrozen Revenue ResultsActual Revenue$983 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Surrozen Q3 2025 Earnings FAQ Did Surrozen beat earnings estimates for Q3 2025? Surrozen (NASDAQ:SRZN) reported earnings of -$3.61 per share for Q3 2025, missing the consensus estimate of -$1.17. The report was announced on Friday, November 7, 2025. What was Surrozen's revenue for Q3 2025? Surrozen reported revenue of $983 thousand for Q3 2025. Surrozen Earnings HeadlinesCantor Fitzgerald Forecasts Strong Price Appreciation for Surrozen (NASDAQ:SRZN) StockNovember 12 at 2:13 AM | americanbankingnews.comSurrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 1:31 AM | marketscreener.comMA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 12 at 1:00 AM | Concord Gold Capital (Ad)Surrozen Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 9 at 4:05 PM | globenewswire.comSurrozen: The Wnt Science Is Compelling, But The Stock Prices In Too Much SuccessNovember 9 at 3:29 PM | seekingalpha.comSurrozen to Present at Upcoming Healthcare Investor ConferenceNovember 6, 2026 | globenewswire.comSee More Surrozen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email. Email Address About SurrozenSurrozen (NASDAQ:SRZN) is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues. Its development programs have focused on potential treatments for diseases involving the liver, gastrointestinal system and other tissues where impaired regeneration contributes to disease. Surrozen’s pipeline has included SZN-043, an investigational Wnt pathway agonist being developed for liver-related conditions, and SZN-1326, an investigational program aimed at gastrointestinal diseases such as ulcerative colitis. The company’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established.View Surrozen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
